Claims for Patent: 10,874,665

Summary for Patent: 10,874,665

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US16/823,807
Patent Claims:	1. A method of treating depression, comprising administering a drug combination comprising: a daily dose of bupropion that is about 150 mg to about 250 mg and a daily dose of dextromethorphan that is about 60 mg to about 100 mg, to a human being in need thereof for at least 8 consecutive days, wherein the bupropion and the dextromethorphan are present in a dosage form, wherein the bupropion and the dextromethorphan are the only therapeutically active compounds in the dosage form; wherein administering the drug combination is more effective in treating depression than administering the same daily dose of the bupropion alone wherein the daily doses of the bupropion and the dextromethorphan are orally administered once a day or are a total of twice daily doses; and wherein the dosage form is formulated for immediate release of dextromethorphan and sustained release of bupropion. 2. The method of claim 1, wherein administering the drug combination is more effective in treating depression than administering the same daily dose of the dextromethorphan alone. 3. The method of claim 1, wherein the daily dose of the bupropion is administered once daily and the daily dose of the dextromethorphan is administered once daily. 4. The method of claim 1, wherein one half of the daily dose of the bupropion is administered twice daily and one half of the daily dose of the dextromethorphan is administered twice daily. 5. The method of claim 1, wherein the drug combination is administered for at least 14 consecutive days. 6. The method of claim 1, wherein the drug combination is administered for at least 30 consecutive days. 7. The method of claim 1, wherein the weight ratio of the dextromethorphan to the bupropion in the drug combination is about 0.3 to about 0.5. 8. The method of claim 1, wherein the drug combination is administered orally. 9. The method of claim 1, wherein the dosage form is a solid dosage form. 10. The method of claim 1, wherein the human being has a Cavgof bupropion that is at least about 10 ng/mL after the drug combination is administered. 11. The method of claim 1, wherein the human being has a Cmax of bupropion that is at least about 90 ng/mL after the drug combination is administered. 12. The method of claim 1, wherein the drug combination comprises: a daily dose of bupropion hydrochloride that is about 210 mg and a daily dose of the dextromethorphan that is about 60 mg to about 100 mg. 13. The method of claim 12, wherein administering the drug combination is more effective in treating depression than administering 105 mg of bupropion hydrochloride twice a day for the same number of consecutive days. 14. The method of claim 1, wherein the depression is major depressive disorder. 15. The method of claim 1, wherein the depression is treatment-resistant depression.